LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 379

Search options

  1. Book ; Online: "No Words for Feelings, yet!". Exploring Alexithymia, Disorder of Affect Regulation and "Mind-Body" Connection

    De Berardis, Domenico / Fornaro, Michele / Orsolini, Laura

    2020  

    Keywords Medicine ; Psychiatry ; Alexithymia ; Affect Regulation ; Neurobiology ; Interventions ; Treatment Models
    Size 1 electronic resource (153 pages)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021231352
    ISBN 9782889660346 ; 2889660346
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Article ; Online: There are no "side" effects, just "core" effects of antipsychotic pharmacotherapy.

    Fornaro, Michele

    Acta psychiatrica Scandinavica

    2021  Volume 143, Issue 2, Page(s) 99–100

    MeSH term(s) Antipsychotic Agents/adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2021-01-16
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 103-x
    ISSN 1600-0447 ; 0001-690X
    ISSN (online) 1600-0447
    ISSN 0001-690X
    DOI 10.1111/acps.13271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Editorial: Comorbidity in bipolar disorder and schizophrenia, volume III.

    Martinotti, Giovanni / Fornaro, Michele / De Berardis, Domenico

    Frontiers in psychiatry

    2024  Volume 14, Page(s) 1356817

    Language English
    Publishing date 2024-01-09
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2564218-2
    ISSN 1664-0640
    ISSN 1664-0640
    DOI 10.3389/fpsyt.2023.1356817
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Editorial: Comorbidity in bipolar disorder, volume II.

    De Berardis, Domenico / Fornaro, Michele / Carmassi, Claudia

    Frontiers in psychiatry

    2023  Volume 14, Page(s) 1115357

    Language English
    Publishing date 2023-02-28
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2564218-2
    ISSN 1664-0640
    ISSN 1664-0640
    DOI 10.3389/fpsyt.2023.1115357
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reply to Dr. Sharma' "Understanding antidepressant tachyphylaxis".

    Fornaro, Michele

    Pharmacological research

    2018  Volume 141, Page(s) 620

    MeSH term(s) Antidepressive Agents ; Depressive Disorder, Major ; Humans ; Tachyphylaxis
    Chemical Substances Antidepressive Agents
    Language English
    Publishing date 2018-11-22
    Publishing country Netherlands
    Document type Letter ; Comment
    ZDB-ID 1003347-6
    ISSN 1096-1186 ; 0031-6989 ; 1043-6618
    ISSN (online) 1096-1186
    ISSN 0031-6989 ; 1043-6618
    DOI 10.1016/j.phrs.2018.11.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Choosing the appropriate pharmacotherapy for obsessive-compulsive disorder in adult patients with comorbid anxiety disorders: clinical and nosological considerations.

    Fornaro, Michele

    Expert opinion on pharmacotherapy

    2018  Volume 20, Issue 2, Page(s) 123–126

    Language English
    Publishing date 2018-11-29
    Publishing country England
    Document type Editorial
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2018.1549225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Reply to Dr. Gentili' "Analysis of tolerance to antidepressant drugs in FDA Adverse Event Reporting System".

    Fornaro, Michele

    Pharmacological research

    2018  Volume 141, Page(s) 618

    MeSH term(s) Adverse Drug Reaction Reporting Systems ; Antidepressive Agents ; Depressive Disorder, Major ; Humans
    Chemical Substances Antidepressive Agents
    Language English
    Publishing date 2018-12-15
    Publishing country Netherlands
    Document type Letter ; Comment
    ZDB-ID 1003347-6
    ISSN 1096-1186 ; 0031-6989 ; 1043-6618
    ISSN (online) 1096-1186
    ISSN 0031-6989 ; 1043-6618
    DOI 10.1016/j.phrs.2018.12.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: An update on the pharmacotherapeutic strategies for the treatment of dysthymic disorder: a systematic review.

    Quagliato, Laiana A / Primavera, Diego / Fornaro, Michele / Preti, Antonio / Carta, Mauro G / Nardi, Antonio E

    Expert opinion on pharmacotherapy

    2024  Volume 24, Issue 18, Page(s) 2035–2040

    Abstract: Introduction: Longer treatment times, more comorbidity, more severe impairments in social, psychological, and emotional functioning, increased healthcare use, and more hospitalizations are all factors that are related to dysthymia. Given the significant ...

    Abstract Introduction: Longer treatment times, more comorbidity, more severe impairments in social, psychological, and emotional functioning, increased healthcare use, and more hospitalizations are all factors that are related to dysthymia. Given the significant prevalence of dysthymia (including persistent depressive disorder) worldwide, its comorbidity with several mental disorders, and the detrimental effects of these comorbidities, it is important to conduct a systematic review to compare the effects of pharmacological acute and maintenance treatments for dysthymia with placebo and standard care in the last 10 years, based on the publication of DSM5.
    Areas covered: This systematic review was performed according to PRISMA guidelines. Databases, including PubMed and Cochrane Central Register of Controlled Trials, were searched to assess the effects of pharmacological acute and maintenance treatments for dysthymia in comparison with placebo and treatment as usual.
    Expert opinion: Our review shows that SSRIs and SNRIs present efficacy for dysthymia treatment, and L-Acetylcarnitine should be investigated further for this condition in elderly patients. The comparison of antidepressant medication versus placebo showed coherent results based on three studies favoring pharmacotherapy as an effective treatment for participants with dysthymia. However, the scarcity of research on continuation and maintenance therapy in people with dysthymia highlights the need for more primary research.
    MeSH term(s) Aged ; Humans ; Antidepressive Agents/therapeutic use ; Comorbidity ; Depressive Disorder/drug therapy ; Dysthymic Disorder/drug therapy ; Selective Serotonin Reuptake Inhibitors/therapeutic use ; Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use
    Chemical Substances Antidepressive Agents ; Selective Serotonin Reuptake Inhibitors ; Serotonin and Noradrenaline Reuptake Inhibitors
    Language English
    Publishing date 2024-01-05
    Publishing country England
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2265809
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Dysregulation of mood, energy, and social rhythms syndrome (DYMERS): A working hypothesis.

    Carta, Mauro Giovanni / Fornaro, Michele / Primavera, Diego / Nardi, Antonio Egidio / Karam, Elie

    Journal of public health research

    2024  Volume 13, Issue 2, Page(s) 22799036241248022

    Abstract: A syndrome centered on the dysregulation of behavioral rhythms (DBR) is discussed. Recent pandemic brought to observe: (1) Having a DBR affecting sleep patterns, eating habits, and social interactions, before the lockdown period, was a determinant for ... ...

    Abstract A syndrome centered on the dysregulation of behavioral rhythms (DBR) is discussed. Recent pandemic brought to observe: (1) Having a DBR affecting sleep patterns, eating habits, and social interactions, before the lockdown period, was a determinant for depressive episodes during the lockdown; (2) In tighter lockdowns, DBR triggered depressive episodes in bipolar patients; (3) DBR in healthcare workers under pressure was a determinant of burnout; (4) DBR influenced the course of chronic diseases by altering immune responses. In addition, it was found that scoring positive on the Mood Disorder Questionnaire (MDQ) was closely associated with the dysregulation of sleep rhythms. MDQ is a screening tool for bipolar disorder (BD), criticized for detecting too many false positives. Studies showed that positivity to the MDQ implied a severe impairment of quality of life even in people without psychiatric diagnoses. According to this evidence, three different hyperactivation levels could be proposed (from normality to pathology): firstly, an adaptive increase in energy (e.g. athletes performing well); secondly, a DBR determined from the continuous stimulation of stress hormones, with possible positive scores on the MDQ without a diagnosis of bipolar disorder, like in burnout syndromes and, thirdly, hyperactivity during manic episodes. The Dysregulation of Mood, Energy, and Social Rhythms Syndrome (DYMERS), the second level of the scale, is proposed as a working hypothesis. DYMERS is also seen as a vulnerable condition that may evolve in other disorders (including BD) according to the individual susceptibility (including genetic predisposition) and the specific nature/level of the stressor.
    Language English
    Publishing date 2024-04-25
    Publishing country United States
    Document type Journal Article
    ISSN 2279-9028
    ISSN 2279-9028
    DOI 10.1177/22799036241248022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The Value of Hearing Aids for the Italian NHS: A Cost-utility Analysis.

    Fornaro, Giulia / Armeni, Patrizio / Albera, Andrea / Barbara, Michele

    Otology & neurotology open

    2022  Volume 2, Issue 4, Page(s) e018

    Abstract: Objective: Hearing loss (HL) prevalence in Italy is expected to increase due to population aging. Hearing aids (HAs) are the main tool for HL rehabilitation; however, cost-utility analyses of HAs are limited. Our objective was to estimate the cost- ... ...

    Abstract Objective: Hearing loss (HL) prevalence in Italy is expected to increase due to population aging. Hearing aids (HAs) are the main tool for HL rehabilitation; however, cost-utility analyses of HAs are limited. Our objective was to estimate the cost-utility of HAs use.
    Study design: Cost-utility analysis.
    Setting: Italian National Healthcare Service, societal perspective.
    Patients interventions and main outcome measures: A multistate Markov model was developed to model a cohort of 55-year-old individuals starting from normal hearing and moving across HL states to compare cost-utility and net monetary benefit of HA use accompanied by post-purchase service, HA use alone, and no treatment. Parameters were estimated using secondary data. Incremental cost-utility ratio (ICUR) and incremental net monetary benefit (INMB) were computed against a €16,625/quality-adjusted life year (QALY) willingness-to-pay (WTP) threshold. Deterministic and probabilistic sensitivity analysis (DSA, PSA) was implemented to assess how uncertainty affected results. Scenario analysis was performed on different assumptions on costs, dropout and compliance rates.
    Results: The model suggests HAs use is a cost-effective strategy compared to no treatment (in the base case: incremental costs €429-€476, incremental QALY gain 0.18 and 0.19, ICUR €2'404/QALY-€2'450/QALY, INMB €2'476-€2'682 for male and female cohort, respectively). By assuming no dropout, INMBs increase up to €10,643-€10,728. DSA highlights that utility weights contribute the most to model uncertainty, PSA shows that the treatment has 97.8%-97.3% probability of being cost-effective at the WTP threshold considered.
    Conclusions: We proposed an original model to assess the cost-utility of HAs use; the application to the Italian setting suggests the treatment is cost-effective, reinforcing the importance of early uptake.
    Language English
    Publishing date 2022-10-26
    Publishing country United States
    Document type Journal Article
    ISSN 2766-3604
    ISSN (online) 2766-3604
    DOI 10.1097/ONO.0000000000000018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top